Howton David T 4

What Happened
David T. Howton, Chief Operating Officer of Solid Biosciences (SLDB), had 14,687 restricted stock units (RSUs) convert into common shares on Feb 13, 2026. Following the vesting/conversion, he sold 7,469 shares in the open market on Feb 18, 2026 for a weighted-average price of $5.82, generating roughly $43,494. The sale was executed to cover withholding taxes related to the RSU vesting (a sell-to-cover), not a discretionary trade.

Key Details

• Transaction dates: Feb 13, 2026 (RSU conversion into shares); Feb 18, 2026 (open-market sale).
• Sale details: 7,469 shares sold at a weighted-average price of $5.82 (prices in the trades ranged $5.23–$6.14), proceeds ≈ $43,494.
• Vesting: 14,687 RSUs converted to shares on Feb 13, 2026. Per the filing, the RSUs were originally granted Feb 13, 2024 and vest 25% each year over four years.
• Tax withholding / sell-to-cover: The sale was made pursuant to a pre-existing durable automatic sales instruction (sell-to-cover) adopted Aug 16, 2024 and was not a discretionary insider sale. (Footnotes F1–F3, F4)
• Net impact from this event: Of the 14,687 shares that converted, 7,469 were sold; the remaining 7,218 shares from this vesting event were retained (based on the numbers reported).
• Filing: Report filed Feb 18, 2026 (covers the Feb 13 conversion and Feb 18 sale). No late-filing flag is indicated in the summary information provided.

Context
This was a routine sell-to-cover following RSU vesting—common for insiders to satisfy tax withholding obligations. The conversion of RSUs into shares is a non-cash derivative settlement; only the sell-to-cover sale generated cash proceeds. Such tax-driven sales are generally not viewed as an independent bullish or bearish signal about company prospects.